US regulatory status: approved. Molecular target: Integrin alpha-IIb/beta-3.
- Target
- Integrin alpha-IIb/beta-3
- Mechanism
- Integrin alpha-V/beta-3 inhibitor
biotech · Colorectal Cancer · Psoriatic Arthritis, Rheumatoid Arthritis · CRDF
Cardiff Oncology
Cardiff Oncology drug portfolio — 62 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
11055 Flintkote Avenue, San Diego, California 92121, US HQ
1999 Founded
51 Employees
Public company Type
CRDF · NYSE Ticker
Company details
- Status
- Public
- HQ
- 11055 Flintkote Avenue, San Diego, California 92121, US
- Founded
- 1999
- Employees
- 51
- Programs
- 58
- Drugs
- 62
- Patents
- 69
Cardiff Oncology pipeline
Portfolio lens on 62 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cardiff Oncology drug portfolio — 62 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Peptidoglycan D,D-transpeptidase MrdA.
- Target
- Peptidoglycan D,D-transpeptidase MrdA
- Mechanism
- Bacterial penicillin-binding protein 2 inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
bimatoprost
Sensory organs (S01)US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.
- Target
- Prostaglandin F2-alpha receptor
- Mechanism
- Prostanoid FP receptor agonist
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cobimetinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Cardiff Oncology's portfolio. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
-
US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
-
US regulatory status: approved. Molecular target: Adrenocorticotropic hormone receptor.
- Target
- Adrenocorticotropic hormone receptor
- Mechanism
- Melanocortin receptor 2 agonist
-
US regulatory status: approved. Molecular target: Vasopressin receptor.
- Target
- Vasopressin receptor
- Mechanism
- Vasopressin receptor agonist
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
folic acid
Various (V04)US regulatory status: approved.
-
gemtuzumab ozogamicin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Myeloid cell surface antigen CD33 binding agent
-
Development asset linked to Cardiff Oncology in public FDA and regional records. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
imatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Cardiff Oncology's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
indacaterol
Respiratory system (R03)Respiratory system (R03) compound in Cardiff Oncology's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Mechanism: Diagnostic.
- Mechanism
- Diagnostic
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
Development asset linked to Cardiff Oncology in public FDA and regional records. Molecular target: Polyunsaturated fatty acid 5-lipoxygenase.
- Target
- Polyunsaturated fatty acid 5-lipoxygenase
- Mechanism
- Arachidonate 5-lipoxygenase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
mycophenolate mofetil
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in Cardiff Oncology's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
plerixafor
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: C-X-C chemokine receptor type 4.
- Target
- C-X-C chemokine receptor type 4
- Mechanism
- C-X-C chemokine receptor type 4 partial agonist
-
ponatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Cardiff Oncology's portfolio. Mechanism: Bcr/Abl fusion protein inhibitor.
- Mechanism
- Bcr/Abl fusion protein inhibitor
-
US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- Bcr/Abl fusion protein inhibitor
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
sirolimus
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
Development asset linked to Cardiff Oncology in public FDA and regional records.
-
tocilizumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.
- Target
- Interleukin-6 receptor subunit alpha
- Mechanism
- Interleukin-6 receptor alpha subunit inhibitor
-
US regulatory status: approved. Molecular target: Peptidoglycan.
- Target
- Peptidoglycan
- Mechanism
- Peptidoglycan inhibitor